Clinical Trials Logo

Coronavirus clinical trials

View clinical trials related to Coronavirus.

Filter by:

NCT ID: NCT04718220 Active, not recruiting - Covid19 Clinical Trials

Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19

STOPCOVID19
Start date: March 1, 2021
Phase: N/A
Study type: Interventional

Pregnant women are a vulnerable and high-risk population, as COVID-19 is associated with an increased risk preterm birth, cesarean section, and maternal critical care. This study will examine the factors that impede testing for SARS-CoV-2 (the causative virus among pregnant women), help determine optimal testing strategies by evaluating the necessity of testing for asymptomatic disease in pregnancy, inform prenatal care plans by assessing the full impact of infection, and contribute to a provider's ability to counsel women and create prenatal care plans if they are pregnant or considering pregnancy.

NCT ID: NCT04715607 Completed - Covid19 Clinical Trials

COVID-19: SARS-CoV-2 Detection in Saliva, Oropharyngeal and Nasopharyngeal Specimens

Start date: January 22, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to compare the SARS-CoV-2 detection rate using either a Saliva, oropharyngeal swabs or nasopharyngeal swab method for specimen collection.

NCT ID: NCT04706416 Completed - Covid19 Clinical Trials

N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)

Start date: November 14, 2020
Phase: Phase 1
Study type: Interventional

This study examines the efficacy of N-acetylglucosamine (NAG) in treating patients with novel coronavirus (COVID-19) infection.

NCT ID: NCT04690413 Completed - COVID-19 Clinical Trials

NOWDx Test for the Detection of Antibodies to COVID-19

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

This study is designed to compare the performance of the NOWDx COVID-19 Test to an emergency use authorized PCR test result. The intent is to show the rapid test device is comparable to a currently marketed device. The NOWDx COVID-19 Test is an in vitro lateral flow immunoassay intended for qualitative detection of total antibodies to SARS-CoV-2 in human whole blood (venous and fingerstick).

NCT ID: NCT04683224 Withdrawn - Covid-19 Clinical Trials

A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine

Start date: February 1, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This is a Phase 2/3, randomized, multicenter, double-blind, dose-response study to evaluate the safety, immunogenicity, and efficacy of UB 612 in 2 age groups, adults 18 to 59 and ≥60 years of age with or without comorbidities.

NCT ID: NCT04674189 Completed - Covid19 Clinical Trials

A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19

Start date: December 23, 2020
Phase: Phase 3
Study type: Interventional

This study aims to evaluate the safety (in all participants) and reactogenicity (in a subset of participants) of CVnCoV administered as a 2-dose schedule to adult participants 18 years of age or older. The study also aims to assess antibody responses to the receptor-binding domain (RBD) of spike (S) protein of SARS-CoV-2 after 1 and 2 doses of CVnCoV in adults 18 years of age or older included in a subset of participants.

NCT ID: NCT04668950 Completed - Covid19 Clinical Trials

Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)

Start date: December 22, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this research study is to determine if a drug called fluvoxamine can be used early in the course of the COVID-19 infection to prevent more serious complications like shortness of breath. Fluvoxamine is an anti-depressant drug approved by the FDA for the treatment of obsessive-compulsive disorder. The use of fluvoxamine for the treatment of COVID-19 is considered investigational, which means the US Food and Drug Administration has not approved it for this use. This study is fully-remote, which means that there is no face-to-face contact; study materials including study drug will be shipped to participants' houses. People around the United States and Canada can participate.

NCT ID: NCT04668209 Terminated - Coronavirus Clinical Trials

Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)

CX4945
Start date: January 21, 2021
Phase: Phase 2
Study type: Interventional

This multi-center, open-label, 2 arm parallel-group, randomized, interventional prospective exploratory study in 40 patients aimed to evaluate safety and explore putative clinical benefits of Silmitasertib 1000 mg BID dose in patients with severe illness caused be SARS-COV-2. This will be a two-arm trial comparing the SOC/best supportive care alone to the SOC/best supportive care with addition of Silmitasertib (allocation ratio 1:1).

NCT ID: NCT04659135 Active, not recruiting - Neoplasms Clinical Trials

ASCO Survey on COVID-19 in Oncology (ASCO) Registry

Start date: April 19, 2020
Phase:
Study type: Observational [Patient Registry]

The American Society of Clinical Oncology (ASCO) Survey on Coronavirus 2019 (COVID-19) in Oncology Registry (ASCO Registry) aims to help the cancer community learn more about the patterns of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 is impacting the delivery of cancer care and patient outcomes. The ASCO Registry collects both baseline and follow-up data on how the virus impacts cancer care and cancer patient outcomes during the COVID-19 pandemic.

NCT ID: NCT04638673 Completed - Covid19 Clinical Trials

NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis

Start date: November 19, 2020
Phase: Phase 2
Study type: Interventional

The purpose of the research is to test out a new form of treatment that examines stimulation of a nerve in the participant's ear. This is called transcutaneous (through the skin) auricular (ear) vagus nerve stimulation (taVNS) which means that the participant will receive stimulation through the ear. The taVNS device looks like an ear bud used with a smart phone or computer. The study team is investigating whether or not taVNS can treat neurologic symptoms of COVID-19 which are termed NEUROCOVID. Some symptoms the participant may experience are new onset anxiety, depression, vertigo, loss of smell, headaches, fatigue, irritability, etc. This study is entirely online and all assessments will be completed virtually.